Overview

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of the combination of Fluzoparib (SHR-3162) and temozolomide with or without SHR-1316 in small cell lung cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Temozolomide